Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, specifically reporting transaction notifications for Periodically Disclosing Market Participants (PDMRs) and Persons Closely Associated (PCAs). The filing details share acquisitions executed on July 1, 2022, on the London Stock Exchange.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Transaction Type | Price per Share | Total Volume |
|---|---|---|---|---|
| 2022-07-01 | Ordinary Shares (25p) | Acquisition (Dividend Re-investment) | £17.6290 | 353 shares |
Note: The total volume of 353 shares is the aggregate of 12 individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document serves as a regulatory disclosure of routine share acquisitions by senior executives and their associates.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were conducted under the Company's Share Reward Plan following the re-investment of dividends paid to shareholders on July 1, 2022.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 11 senior executives (including the CEO, Chief People Officer, and various Presidents/SVPs) and one PCA.
- Share Price: The uniform execution price for all transactions was £17.6290 per share.
- Volume: Individual transaction volumes were small, ranging from 3 to 61 shares per person.
- Scope: This filing does not provide data on GSK's overall financial health, revenue, or earnings for the period.